Our research in immunology

At Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in dermatology, gastroenterology, pulmonology and rheumatology. We have spent the last two decades pioneering new treatments and continually innovating to modulate the body’s immune response to treat disease. We strive to deliver truly transformational science at an accelerated speed — making durable remissions and cures a reality for more patients faster than ever.

Featured in immunology

Intended for healthcare professionals, scientific audiences and media.  

Our goal is to restore some of what immune-mediated diseases have taken away — empowering patients and their loved ones to take back their lives.

As part of our vision to transform patients' lives through science, BMS is committed to developing transformational therapies with the potential for long-lasting remission for patients with immune-mediated diseases.

Explore our stories

Our sequential immunotherapy framework

As proven pioneers in modulating the body’s immune response, Bristol Myers Squibb continues to pursue pathbreaking science by pushing the boundaries in immune-mediated diseases. Our sequential immunotherapy framework aims to address the root cause of disease by controlling inflammation, resetting the immune system and maintaining the renewed homeostasis – a balancing act akin to leveling out a tipping scale – fueled by a passion to deliver transformational benefits for patients in need.

Our immunology focus areas​

Dermatology at BMS

Through our pioneering exploration of immune pathways implicated in dermatologic conditions, our discovery team’s research is leading to the potential for safe, effective, category-defining new therapies that may address the pressing treatment gaps that continue to exist for people living with these conditions. With a highly focused pipeline, we are pursuing novel treatments for psoriasis and exploring a broad range of serious dermatologic conditions in our early research.

Scientific and disease-state resources

Explore our stories

Gastroenterology at BMS

We are pursuing innovative research to potentially change the course of gastrointestinal immune-mediated diseases, including inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, and eosinophilic esophagitis (EoE). Our scientific innovations have the potential to provide relief and remission to people living with these conditions.

Scientific and disease-state resources

Learn about eosinophilic esophagitis (EoE) and Bristol Myers Squibb's research in this video from Estelle Vester-Blokland, senior vice president, Medical International Markets.


Explore our stories

Pulmonology at BMS

We are committed to applying its expertise regarding the role of fibrosis in the development of several immune-mediated diseases to advance new treatments that go beyond symptom relief and address the underlying cause of diseases such as pulmonary fibrosis and other pulmonary diseases. 

Scientific and disease-state resources

Explore our stories

Rheumatology at BMS

Over 20 years ago, we pioneered the science of modulating the body’s immune response to treat disease, beginning with our research in rheumatoid arthritis (RA). Building on that foundation, we continue to pursue pathbreaking science across rheumatic diseases including RA, psoriatic arthritis, lupus and Sjögren’s disease. Fueled by the possibility to help more patients, we are following the science to tailor therapies to individual needs, improve outcomes and expand treatment options.

Scientific and disease-state resources

Explore our stories

Explore our scientific resources

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.